Affiliation:
1. Katedra Genetyki Molekularnej, Wydział Biologii i Ochrony Środowiska, Uniwersytet Łódzki
Abstract
Cancer research is among the key challenges in current medicine and biology. Many decades of investigations have brought measurable benefits in both areas with regard to expanding the knowledge of the molecular mechanism of cancer and developing treatment strategies. Despite that cancers are still among diseases with the highest mortality rate, and cancer treatment is often unsuccessful and connected with severe side effects. The development of therapeutic strategies in both targeting the primary tumor origin and preventing metastasis is largely based on testing newly synthesized chemical agents, including a group of metal-containing complexes. It seems that ruthenium-containing complexes are of high potential in cancer therapy, and our work presents the current data about the application of ruthenium-based complexes − NAMI-A and KP1019 in cancer therapy.
Subject
Infectious Diseases,Microbiology (medical)
Reference62 articles.
1. Abid M., Shamsi F., Azam A.: Ruthenium complexes: An emergingground to the development of metallopharmaceuticals for cancertherapy. Mini Rev. Med. Chem., 2016; 16: 772–786
2. Adeel M.M., Qasim M., Ashfaq U.A., Masoud M.S., Rehman M.U.,Qamar M.T., Javed M.R.: Modelling and simulation of mutant allelesof breast cancer metastasis suppressor 1 (BRMS1) gene. Bioinformation,2014; 10: 454–459
3. Alessio E.: Thirty years of the drug candidate NAMI‐A and themyths in the field of ruthenium anticancer compounds: A personalperspective. Eur. J. Inorg. Chem., 2017: 1549–1560
4. Alessio E., Messori L.: The deceptively similar ruthenium(III) drugcandidates KP1019 and NAMI-A have different actions. What didwe learn in the past 30 years? Met. Ions Life Sci., 2018; 18: 141–170
5. Alessio E., Messori L.: NAMI-A and KP1019/1339, two iconic rutheniumanticancer drug candidates face-to-face: A case story inmedicinal inorganic chemistry. Molecules, 2019; 24: 1995